Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prognostic variables in osteosarcoma: a multi-institutional study.

W F Taylor1, J C Ivins, K K Unni

  • 1Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905.

Journal of the National Cancer Institute
|January 4, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effective Surface Passivation of InP Nanowires by Atomic-Layer-Deposited Al<sub>2</sub>O<sub>3</sub> with PO<sub>x</sub> Interlayer.

Nano letters·2017
Same author

Ultralow Surface Recombination Velocity in Passivated InGaAs/InP Nanopillars.

Nano letters·2017
Same author

Pigmented villonodular synovitis.

Orthopedics·2014
Same author

Synovial sarcoma.

Orthopedics·2014
Same author

Chondroblastoma.

Orthopedics·2014
Same author

Mayo clinic tumor rounds.

Orthopedics·2014
Same journal

Response to Wang et al. and Shen et al.

Journal of the National Cancer Institute·2026
Same journal

Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE.

Journal of the National Cancer Institute·2026
Same journal

Beyond R2: Assessing quality of trial level surrogate endpoints in colorectal cancer.

Journal of the National Cancer Institute·2026
Same journal

A novel classification of small bowel adenocarcinoma based on the hidden genome classifier: a multi-institutional study.

Journal of the National Cancer Institute·2026
Same journal

Response to Yu, Wang and Ge.

Journal of the National Cancer Institute·2026
Same journal

Re: Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma.

Journal of the National Cancer Institute·2026
See all related articles

This study identified nine key indicators for osteosarcoma survival, including tumor characteristics and patient symptoms. Unexpectedly, treatment type did not significantly impact survival rates in this comprehensive cancer center analysis.

Area of Science:

  • Oncology
  • Medical Statistics

Background:

  • Osteosarcoma is a rare bone cancer requiring identification of prognostic factors.
  • Previous studies have explored various indicators, but a comprehensive analysis across multiple institutions was needed.

Purpose of the Study:

  • To identify prognostic indicators for osteosarcoma survival.
  • To develop a prognostic score for predicting patient outcomes.
  • To compare the effectiveness of different treatment modalities for osteosarcoma.

Main Methods:

  • Multi-institutional study of 543 osteosarcoma patients (1977-1982).
  • Analysis of 38 patient characteristics, 3 treatment categories, and institutional variables.
  • Development of a prognostic score using Cox regression (step-down) analysis.

Related Experiment Videos

Main Results:

  • A combination of nine factors (morphology, site, spread, grade, size, symptom duration, weight loss, swelling, lytic appearance) best predicted survival.
  • Treatment modality was not a significant prognostic indicator.
  • Adjusting for prognostic factors eliminated observed differences in progression rates between amputation and resection, and between complete and incomplete surgery.

Conclusions:

  • Prognostic indicators for osteosarcoma are primarily patient and tumor characteristics, not treatment type.
  • A validated prognostic score can aid in risk stratification for osteosarcoma patients.
  • Surgical approach (complete vs. incomplete) impacts disease progression but not mortality when adjusted for prognostic factors.